Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
Earnings for Icosavax, Inc. (ICVX)
Earnings in 2022 (TTM): $-91,758,000
According to Icosavax, Inc.'s latest financial reports the company's current earnings (TTM) are $-91,758,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Icosavax, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-91,758,000 | $-88,458,000 |
| 2021 | $-66,971,000 | $-67,999,000 |
| 2020 | $-18,854,000 | $-19,185,000 |
| 2019 | $-5,297,000 | $-5,196,000 |